Results 51 to 60 of about 689,752 (349)

Prognostic value of LIPC in non-small cell lung carcinoma [PDF]

Cell Cycle, 2013
Non-small cell lung carcinoma (NSCLC) is the most common form of lung cancer and is associated with a high mortality rate worldwide. The majority of individuals bearing NSCLC are treated with surgery plus adjuvant cisplatin, an initially effective therapeutic regimen that, however, is unable to prevent relapse within 5 years after tumor resection in an
Pierre Validire, Ilio Vitale, Angélique Robin, Lorenzo Galluzzi, Ignacio I. Wistuba, Pierre Fouret, Ken A. Olaussen, Aicha Goubar, Jean-Charles Soria, Benjamin Besse, Nicolas Dorvault, Laura Senovilla, Guido Kroemer, Judith Michels, Carmen Behrens   +14 more
openaire   +6 more sources

An unusual presentation of non-small cell lung carcinoma

Case Reports, 2009
Lung cancer is the most common malignancy in the Western world and usually presents with respiratory symptoms. The diagnosis of lung cancer is normally made by chest radiography followed by histological confirmation with either radiological or endoscopically guided biopsies. Very rarely, imaging does not help with the initial diagnosis. Haematuria is a
Phillip M T Weston, Mohantha Deevan Dooldeniya, C Shekhar Biyani   +2 more
openaire   +4 more sources

Improving diagnosis and prognosis of lung cancer using vision transformers: A scoping review [PDF]

arXiv, 2023
Vision transformer-based methods are advancing the field of medical artificial intelligence and cancer imaging, including lung cancer applications. Recently, many researchers have developed vision transformer-based AI methods for lung cancer diagnosis and prognosis.
arxiv  

The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer

Cancer immunology research, 2020
The gut microbiome influences the efficacy of immune checkpoint inhibition (ICI). In non–small cell lung carcinoma patients, antibiotics have a negative impact on ICI efficacy, correlating to enrichment of Ruminococcaceae UCG 13 and Agathobacter in the ...
T. Hakozaki, C. Richard, A. Elkrief, Y. Hosomi, M. Benlaïfaoui, Iris L Mimpen, S. Terrisse, L. Derosa, L. Zitvogel, B. Routy, Y. Okuma   +10 more
semanticscholar   +1 more source

Joint co-clustering: co-clustering of genomic and clinical bioimaging data [PDF]

, 2007
For better understanding the genetic mechanisms underlying clinical observations, and better defining a group of potential candidates for protein-family-inhibiting therapy, it is interesting to determine the correlations between genomic, clinical data ...
Aho, Amann, Aurenhammer, Brabender, Brey, Bullinger, Chen, Dacic, Draghici, Elisa Ficarra, Elmoataz, Enrico Macii, Ficarra, Gebhardt, Giovanni De Micheli, Hengerer, Jacob, Kersting, Kittler, Luca Benini, Malpica, McInerney, Mukherjee, Otsu, Ridler, Ruifrok, Saviozzi, Sungroh Yoon, Suzuki, Taneja, Tidow, Troyanskaya, Tusher, Yang, Yoon, Zheng, Zhou   +36 more
core   +2 more sources

Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)

Clinical Cancer Research, 2018
Purpose: KEAP1 and NFE2L2 mutations are associated with impaired prognosis in a variety of cancers and with squamous cell carcinoma formation in non–small cell lung cancer (NSCLC). However, little is known about frequency, histology dependence, molecular
R. Frank, M. Scheffler, S. Merkelbach-Bruse, M. Ihle, A. Kron, Michael Rauer, F. Ueckeroth, K. König, S. Michels, R. Fischer, A. Eisert, J. Fassunke, C. Heydt, M. Serke, Y. Ko, U. Gerigk, T. Geist, B. Kaminsky, L. Heukamp, M. Clément-Ziza, R. Büttner, J. Wolf   +21 more
semanticscholar   +1 more source

Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma [PDF]

, 2014
Lineage transition in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) of non-small cell lung cancer, as implicated by clinical observation of mixed ADC and SCC pathologies in adenosquamous cell carcinoma, remains a fundamental yet unsolved ...
Chen, Haiquan, Fang, Jing, Fang, Rong, Fang, Zhaoyuan, Gao, Yijun, Ge, Gaoxiang, Han, Xiangkun, Hou, Yingyong, Ji, Hongbin, Li, Fei, Li, Fuming, Li, Li, Ma, Huimin, Sun, Yihua, Wang, Hongda, Wong, Kwok-kin, Xiao, Qian, Yao, Shun, Zhang, Lei, Zhang, Wenjing   +19 more
core   +1 more source

Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma [PDF]

Journal of Cancer Research Updates, 2013
Lung cancer is the most commonly diagnosed cancer in the world. “Driver” and “passenger” mutations identified in lung cancer indicate that genetics play a major role in the development of the disease, progression, metastasis and response to therapy.
Elizabeth Hopper-Borge, Janet Wangari-Talbot   +1 more
openaire   +3 more sources

Zero-Shot and Few-Shot Learning for Lung Cancer Multi-Label Classification using Vision Transformer [PDF]

arXiv, 2022
Lung cancer is the leading cause of cancer-related death worldwide. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the most common histologic subtypes of non-small-cell lung cancer (NSCLC). Histology is an essential tool for lung cancer diagnosis. Pathologists make classifications according to the dominant subtypes.
arxiv  

Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature

Lung India, 2018
A subset of non-small cell lung carcinoma (NSCC) harbor active mutations of epidermal growth factor receptor (EGFR). In these, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the first-line treatment.
Monalisa Hui, Shantveer G Uppin, Bala Joseph Stalin, G Sadashivudu   +3 more
doaj   +1 more source